Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first Hanf.com in the...
2025-06-06 7:30 AM EDT
Neural Therapeutics and Hanf.com Sign Strategic Investment and Option Agreement to Create a Science-Backed Botanical Wellness Leader
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading German CBD retailer, are pleased to announce the signing of a strategic investment and option agreement dated May 28, 2025 (the "SIO Agreement") for Neural to acquire an interest in CWE through a...
2025-05-28 1:52 PM EDT
Neural Therapeutics Announces RSU and Options Grant
Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, announces that the Board of Directors approved the grant of 2,720,000 restricted share units ("RSUs") and 725,000 stock options ("Options").RSUs were granted to directors and consultants of Neural in accordance with the provisions of the RSU Plan that is available on the Company's...
2025-05-13 4:31 PM EDT
Neural Therapeutics Announces SERFOR Permit Renewal Submission and Extension of LOI with HANF.COM
Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to Servicio Nacional Forestal y de Fauna Silvestre ("SERFOR"). SERFOR a specialized Peruvian technical governmental agency under the Ministry of Agriculture, responsible for regulating forest and wildlife matters, as well as...
2025-05-09 8:26 AM EDT
Neural Therapeutics Strengthens IP Portfolio With a Patent Application
Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline DosesExtraction Technology Delivering Higher Yields and Greater PurityFrankfurt Stock Exchange Ticker Symbol Changed to "HANF"Extension of LOI with CWE European Holdings (dba Hanf.com) Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illness
2025-04-14 8:52 AM EDT
Neural Therapeutics Commences Trading on Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - March 31, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the Frankfurt Stock Exchange under ticker symbol "M6B".Neural CEO Ian Campbell commented, "Listing our shares on a Frankfurt Stock Exchange will provide us with access to an expanded international investor...
2025-03-31 8:22 AM EDT
Neural Therapeutics Commences Trading, Provides Update on Growth Initiatives and Engages Investor Relations Consultants
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - Neural Therapeutics Inc. (CSE: NURL) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange ("CSE") under the symbol "NURL" on Monday, March 17, 2025.With the listing process completed and the Series A Financing closed, Neural will now focus on advancing its mescaline-based therapy...
2025-03-17 7:30 AM EDT
Neural Therapeutics Announces Closing of Financing, CSE Listing Approval, Completion of Previously Announced Transactions and Corporate Updates
Toronto, Ontario--(Newsfile Corp. - March 13, 2025) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has completed the final tranche of its previously announced private placement ("Series A Financing") and has received conditional approval ("Conditional Approval") to list its common shares ("Neural Shares") on the Canadian Securities Exchange ("CSE") under the ticker symbol "NURL". Neural also...
2025-03-13 7:29 AM EDT
Neural Therapeutics Announces Changes to Board of Directors and Completion of Debt Settlement
Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioids, wishes to announce that Alex Storcheus and Eran Ovadya were appointed as directors to the Neural board.John Durfy, Chairman of Neural commented: "We are pleased to welcome Alex and Edan to Neural's board of directors. As we continue to work towards completing a...
2024-12-16 7:30 AM EST
Neural Therapeutics Undertakes Multiple Initiatives to Defer and Eliminate a Significant Portion of Financial Obligations
Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic treatments for mental health conditions related to substance use disorders, is pleased to announce it has entered into a number of agreements with related parties and third parties that result in deferral and conversion of a significant amount of financial obligations, and elimination of certain general and administrative expenses on a go-forward basis.Ian Campbell, CEO of...
2024-11-25 7:32 AM EST
Neural Therapeutics Inc. Announces Letter of Intent with Leading German Hemp-Based Product Retailer "Hanf.com"
Toronto, Ontario--(Newsfile Corp. - October 3, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic treatments for mental health conditions related to substance use disorders, is pleased to announce that it has signed a non-binding letter of intent ("LOI") to acquire an interest in CWE European Holdings Inc., ("CWE" or "HANF"), a prominent hemp-based product retailer in Germany. CWE owns and operates both physical and online stores, with 12 locations in...
2024-10-03 7:32 AM EDT
Neural Therapeutics Announces Changes to Board of Directors and Advisors
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioids, wishes to announce that Dr. Kelly Narine and Professor Jason Dyck have resigned as directors of Neural, and Dr. Carlos Davidovich was appointed as a new director.John Durfy, Chairman of Neural commented: "We extend our deepest gratitude to Professor Jason Dyke and Dr....
2024-06-27 12:00 PM EDT
Neural Therapeutics Receives Conditional Approval to Listing on the CSE and Announces Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - May 8, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental ailments related to substance use disorders, is pleased to announce that it has received conditional approval ("Conditional Approval") to list its common shares ("Neural Shares") on the Canadian Securities Exchange ("CSE") under the ticker symbol "NURL".Conditional Approval to List on the CSEThe Conditional Approval to list Neural Shares on the CSE ("Listing") is...
2024-05-08 7:30 AM EDT
Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the formal appointment of Dr. Jason Dyck, Dr. Kelly Narine and Colin McLelland to the Company's board of directors. The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").Ian Campbell, Neural CEO, commented, "While we've been collaborating with Dr. Narine, Dr, Dyck and Mr. McLelland for almost two...
2023-10-03 7:30 AM EDT
Neural Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement and Change of Auditors
Toronto, Ontario--(Newsfile Corp. - October 2, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug-discovery and development company, is pleased to announce that it has closed the first tranche of the private placement ("Private Placement") for gross proceeds of $293,346.42 and completed debt settlement of approximately $327,845.49 ("Debt Settlement"). Ian Campbell, CEO of Neural Therapeutics commented: "While the capital markets environment for junior life sciences companies remains challenging, we are very grateful for the support of our...
2023-10-02 4:30 PM EDT
Neural Therapeutics Receives Key Permission from Peruvian Government to Harvest and Work with the San Pedro Cactus Containing Mescaline
Permission enables company to conduct research with potentially patentable outcomesRare permission granted due to Company's commitment to knowledge transfer and species preservationResearch Partnership with Universidad Peruana Cayetano HerediaToronto, Ontario--(Newsfile Corp. - July 27, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce that after nearly 11 months of a rigorous review process, the Company has received a key permission from Servicio Nacional Forestal y de Fauna Silvestre ("SERFOR"), the National Service for Forest and Wildlife, part...
2023-07-27 7:30 AM EDT
Neural Therapeutics Inc. Closes Rights Offering
Toronto, Ontario--(Newsfile Corp. - July 14, 2023) - Neural Therapeutics Inc. (the "Company" or "Neural"), an ethnobotanical drug-discovery and development company, is pleased to announce that it has closed its previously announced rights offering which expired on July 7, 2023 (the "Rights Offering").In connection with the closing of the Rights Offering, the Company issued 5,595,992 common shares in the capital of Neural (the "Neural Shares") at the subscription price of $0.03 per Neural Share for total gross proceeds of approximately...
2023-07-14 5:00 PM EDT
Neural Therapeutics Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to provide the following corporate update, describing the progress made with the execution of the corporate strategy towards developing a mescaline-based psychedelic for mental health treatment.Spin-Out Completed and DTC Eligibility ReceivedOn May 23, 2023, Neural completed its spin-out from Vertical Peak Holdings Inc. (formerly High Fusion Inc.), as a result of which, Neural became a stand-alone reporting issuer and is now working towards...
2023-06-20 8:13 AM EDT
Neural Therapeutics Inc. Announces Launch of Rights Offering and Concurrent Private Placement
Toronto, Ontario--(Newsfile Corp. - June 13, 2023) - Neural Therapeutics Inc. (the "Company" or "Neural") an ethnobotanical drug-discovery and development company announces it is undertaking a rights offering to raise gross proceeds of up to $1,184,080 (the "Rights Offering") and a non-brokered private placement of up to $900,000 ("Concurrent Private Placement"). Ian Campbell, CEO of Neural commented: "While the overall capital market conditions for junior life sciences companies continue to be volatile, we remain committed to advancing our business plan...
2023-06-13 5:09 PM EDT